Table 1.
Interferon-based antiviral treatment in hepatitis C virus-infected patients with low-grade non-Hodgkin lymphomas
| Year | No. of patients | Diagnosis | Genotypes | Cryoglobulinemia | Antiviral treatment | Virologic response | NHL response | |
| Bauduer[35] | 1996 | 1 | MZL of MALT (oral cavity) | NA | - | α-IFN | 1 | 1 PR |
| Caramaschi et al[36] | 1999 | 1 | MZL of MALT (salivary glands) | NA | - | α-IFN | NA | 1 CR |
| Moccia et al[37] | 1999 | 3 | SMZL | NA | - | α-IFN | NA | 2 CR |
| Patriarca et al[38] | 2001 | 1 | LPL | 2a/2c | - | α-IFN | 1 | 1 CR |
| Hermine et al[30] | 2002 | 9 | SLVL | NA | 6 | α-IFN | 7 | 7 CR |
| Casato et al[39] | 2002 | 1 | Leukemic MZL | NA | 1 | α-IFN | Decreased HCV-RNA | 1 CR |
| Pitini et al[63] | 2004 | 2 | SMZL | NA | - | α-IFN | 2 | 2 CR |
| Tursi et al[64] | 2004 | 16 | MZL of MALT (stomach) | NA | - | α-IFN-2b + RBV | 11/16 | 16 CR |
| Kelaidi et al[41] | 2004 | 8 | SMZL (n = 4) | 3a (n = 1), 5a (n = 1) | 8 | α-IFN-2b + RBV | 5 SVR, 2 PR | 5 CR |
| Disseminated MZL (n = 1) | - | |||||||
| Leukemic MZL (n = 1) | 1b | |||||||
| MZL of MALT (n = 2) (1 duodenus; 1 ileus) | 4c/4d | |||||||
| Vallisa et al[42] | 2005 | 13 | SMZL (n = 4) | 1b (n = 2), 2b (n = 1) | 5 | Peg-IFN + RBV | 7 SVR, 1 PR | 7 CR, 2 PR |
| NMZL (n = 2) | 2a/2c (n = 1), 1b (n = 1) | |||||||
| MZL of MALT (n = 2) | 1b (n = 2) | |||||||
| FL (n = 1) | 2a | |||||||
| LPL (n = 4) | 2a/2c (n = 1), 1b (n = 1), | |||||||
| na (n = 2) | ||||||||
| Svoboda et al[65] | 2005 | 1 | MZL of MALT (salivary gland, liver) | 2b | - | Peg-IFN + RBV | 1 | CR |
| Saadoun et al[24] | 2005 | 18 | SLVL | 1 (n = 7) | 18 | α-IFN (+ RBV in 10) | 14 CR, 4 PR | 14 CR, 4 PR |
| 2 (n = 4) | ||||||||
| 3 (n = 1) | ||||||||
| 4 (n = 1) | ||||||||
| Paulli et al[25] | 2009 | 2 | Subcutaneous MZL of MALT | 2a/2c, 2b | 2 | Peg-IFN + RBV | 2 CR | 1 CR, 1 PR |
| Mazzaro et al[43] | 2009 | 18 | 1 SLVL | 1b (n = 11) | 13 | α -IFN + RBV (n = 8) | 9 SVR | 9 CR, 4 PR |
| 1 FL | 2a/2c (n = 7) | Peg-IFN + RBV (n = 10) | ||||||
| 16 LPL | ||||||||
| Oda et al[66] | 2010 | 1 | B-NHL (liver) | 2a | - | Peg-IFN + RBV | SVR | CR |
| Pellicelli et al[67] | 2011 | 9 | 3 SMZL | 1b (n = 2) | 4 | Peg-IFN + RBV | 7 SVR | 5 CR, 2 PR |
| 3 MZL of MALT | 2 (n = 2) | |||||||
| 1 NMZL | 2a (n = 2) | |||||||
| 2 FL | 2a/2c (n = 3) | |||||||
| Mauro et al[68] | 2012 | 1 | LPL | 1b | 1 | Peg-IFN + RBV (2nd line) | SVR | CR |
| Arcaini et al[45] | 2014 | 100 | 23 SMZL | 1 (n = 37) | 34 | α-IFN (n = 33) (+ RBV in 26) | 80% SVR | 44% CR, 33% PR |
| (1st-line) | 12 NMZL | 2 (n = 52) | Peg-IFN (n = 67) (+ RBV in 57) | |||||
| 25 MZL of MALT | 3 (n = 5) | |||||||
| 7 LPL | 5 (n = 1) | |||||||
| 5 FL | NA (n = 5) | |||||||
| 1 SLL | ||||||||
| 27 Low-grade NHL NOS | ||||||||
| 34 | 12 SMZL | 1 (n = 15) | 10 | α-IFN (n = 14) (+ RBV in 10) | 67% SVR | 56% CR, 29% PR | ||
| (2nd-line) | 2 NMZL | 2 (n = 13) | Peg-IFN (n = 20) (+ RBV in 15) | |||||
| 6 MZL of MALT | 3 (n = 2) | |||||||
| 2 LPL | 5 (n = 1) | |||||||
| 7 FL | NA (n = 4) | |||||||
| 3 SLL | ||||||||
| 2 Low-grade NHL NOS | ||||||||
| Michot et al[28] | 2015 | 14 | 14 MZL | NA | NA | Peg-IFN + RBV (n = 12) | 79% SVR (AT alone) | 57% CR, 21% PR |
| (AT alone) | ||||||||
| 8 (At + Rituximab) | 8 MZL | NA | NA | PegIFN + RBV + 4 Rituximab (n = 8) | NA (AT + Rituximab) | 38% CR, 62% PR |
SMZL: Splenic marginal zone lymphoma; NMZL: Nodal marginal zone lymphoma; SLVL: Splenic lymphoma with villous lymphocytes; MZL: Marginal zone lymphoma; FL: Follicular lymphoma; LPL: Lymphoplasmacytic lymphoma; MCL: Mantle cell lymphoma; SLL: Small lymphocytic lymphoma; NHL: Non-Hodgkin lymphoma; NOS: Not otherwise specified; IFN: Interferon; RBV: Ribavirine; CR: Complete response; PR: Partial response; SVR: Sustained virologic response.